GlassScriptPhysician profile
Paulin Gotrace
NPI 1538690813
$1,028.75
in general payments reported to CMS, 2019-2025
12 companies · $240 in 2025
The $240 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $37.39 · 2021: $47.52 · 2022: $24.43 · 2023: $443 · 2024: $236 · 2025: $240.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $919.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $919.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $250.19 | 2023-2025 | Dovato, Apretude |
| Exact Sciences Corporation | $198.85 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Janssen Biotech, INC. | $119.68 | 2022-2023 | Symtuza, Prezcobix |
| Hologic Sales and Service, LLC | $91.68 | 2023-2024 | Aptima, Thinprep 2000 Processor |
| Lilly USA, LLC | $78.45 | 2020-2024 | Mounjaro, Jardiance, Zepbound |
| Gilead Sciences, INC. | $75.63 | 2023-2025 | |
| Abbott Laboratories | $60.87 | 2021-2024 | Proclaim, Freestyle Libre |
| Boehringer Ingelheim Pharmaceuticals, INC. | $60.60 | 2020-2023 | Jardiance |
| Merck Sharp & Dohme LLC | $46.77 | 2024-2025 | Pifeltro, Delstrigo |
| Organon LLC | $18.67 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $14.63 | 2023 | Farxiga |
| Glaxosmithkline, LLC. | $12.73 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paulin Gotrace listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.